COVID-19
Excerpt from the article: Fluvoxamine, an antidepressant used to treat obsessive-compulsive disorder, may help prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19), results of an early clinical trial suggest. The double-blind, placebo-controlled, randomized study, published in JAMA, included 152 outpatients with COVID-19 in the St. Louis area between April 10 and August…
Read More
Excerpt from the Press Release: Celltrion Group has completed enrolment of 327 patients with mild-to-moderate SARS-CoV-2 infection symptoms to evaluate anti-Covid-19 monoclonal antibody treatment candidate CT-P59 in the global Phase II clinical trial. Celltrion Group has completed enrolment of 327 patients with mild-to-moderate SARS-CoV-2 infection symptoms to evaluate anti-Covid-19 monoclonal antibody treatment candidate CT-P59 in…
Read More
Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Adagio Therapeutics, Inc., today pre-published in vitro and in vivo data demonstrating its lead antibody candidate, ADG2, shows similar or higher potency against SARS-CoV-2 compared to monoclonal antibodies (mAbs) in clinical development, while also uniquely offering broad neutralization against a range of sarbecoviruses that pose a threat to…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced COVID-19 Community Connect, a program to link federal, state and local governmental entities, public health agencies, academic institutions, workforces, individuals and…
Read More
Excerpt from the Press Release: RADNOR, Pa. and GENEVA, Nov. 13, 2020 /PRNewswire/ — NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF,OTCBB:RLFTF) (“Relief”) announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100™ (aviptadil) for treating respiratory failure in patients with Critical…
Read More
Excerpt from the Press Release: Phlexglobal, a leading innovative technology and services provider for the life sciences industry, today announces that Hope Biosciences Stem Cell Research Foundation has selected Phlexglobal’s advanced SaaS solution, PhlexSubmission, to enhance the efficiency and quality of its eCTD submissions process. As an organization dedicated to advancing research through innovative protocols…
Read More
Excerpt from the Press Release: SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it is filing an investigational new drug application (IND) for intravenous (IV) COVI-AMG (STI-2020) to treat COVID-19 patients with mild symptoms and to evaluate safety and pharmacokinetics in healthy volunteers. Sorrento has previously…
Read More
Excerpt from the Article: Researchers at Stanford University have developed a CRISPR-based “lab on a chip” to detect COVID-19, and are working with automakers at Ford to develop their prototype into a market-ready product. This could provide an automated, hand-held device designed to deliver a coronavirus test result anywhere within 30 minutes. In a study…
Read More
Excerpt from the Article: Hopes of finding a magic bullet against Covid-19, at least within the next few months, rest on the outcomes of a small number of clinical trials. Beyond these leading antibody and vaccine approaches, few large clinical programmes of other novel mechanisms are under way. True, there is a huge amount of…
Read More
Excerpt from the Press Release: RADNOR, Pa. and GENEVA, Nov. 5, 2020 /PRNewswire/ — NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF,OTCBB:RLFTF) (“Relief”) announced that the independent Data Monitoring Committee (DMC) met yesterday and voted unanimously that NCT 04311697 should continue as planned to its full enrollment of 165 patients. Specifically, the committee identified no safety concerns…
Read More